




(Rev. 5/92) Comparable to Form PTO-1449				U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. TSRI 651.3		Serial No. 09/538,248	
				Applicant CHERESH, David A., et al.					
				Filing Date March 29, 2000				Group	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									
U.S. PATENT DOCUMENTS									
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
RP	*	4,797,368	1/10/89	Carter et al.	435	320			
	*	5,173,414	12/22/92	Lebkowski et al.	435	172.3			
	*	5,436,146	7/25/95	Shenk et al.	435	172.3			
	*	5,589,377	12/31/96	Lebkowski et al.	435	240.2			
	*	5,670,488	9/23/97	Gregory et al.	514	44			
	*	5,589,466	12/31/96	Felgner et al.	514	44			
	*	4,356,167	10/26/82	Kelly	424	38			
	*	5,580,575	12/3/96	Unger et al.	424	450			
	*	5,542,935	8/6/96	Unger et al.	604	190			
	*	5,643,599	7/1/97	Lee et al.	424	450			
RP	*	5,631,237	5/20/97	Dzau et al.	514	44			
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
RP	*	Bett et al., 1994, "An efficient and flexible system for construction of adenovirus vectors with insertions and deletions in early regions 1 and 3" PNAS (USA) 91: 8802-8806							
RP	*	Brooks et al., 1994, "Requirement of vascular integrin $\alpha V\beta 3$ for angiogenesis" Science 264: 569-571							
RP	*	Brooks et al., 1994, "Integrin $\alpha V\beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels" Cell 79: 1157-1164							
Examiner Rebecca Parity				Date Considered 3-4-02					
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

(Rev. 5/92) Comparable to Form PTO-1449				U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. <b>TSRI 651.3</b>		Serial No. <b>09/538,248</b>	
				Applicant <b>CHERESH, David A., et al.</b>					
				Filing Date <b>March 29, 2000</b>				Group	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									
U.S. PATENT DOCUMENTS									
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
RP	*	Brooks et al., 1996, "Localization of Matrix Metalloprotease MMP-2 to the Surface of Invasive Cells by Interaction with Integrin $\alpha V\beta 3$ " Cell 85: 683-691							
	*	Broome et al., 1996, "Requirement for c-Src catalytic activity and SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signalling" J. Biol. Chem. 271: 16798-16806							
	*	Bull et al., 1994, "Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells" FEBS Letters, 360:41-44							
	*	Chang et al., 1995, "Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty" J. Clin. Inves. 96: 2260-2268							
	*	Connolly et al., 1989, "Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis" J. Clin. Inves. 84: 1470-1478							
	*	Courtneidge et al., 1993, "The Src family of protein tyrosine kinases: regulation and functions" Dev. Suppl. 57-64							
	*	Dvorak et al., 1995, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis" Am.J.Pathol. 146(5):1029-1039							
RP	*	Eliceiri et al., 1999, "Selective requirement for Src Kinases during VEGF-induced angiogenesis and vascular permeability" Molecular Cell 4: 915-924							
Examiner				Date Considered					
Rebecca Parity				3-4-02					
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

(Rev. 5/92)  
Comparable to  
Form PTO-1449



U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
**TSRI 651.3**

Serial No.  
**09/538,248**

Applicant  
**CHERESH, David A., et al.**

Filing Date  
**March 29, 2000**

Group

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

### U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RF	*	Eriksson et al., 1980, "Method for in vivo microscopy of the cutaneous microcirculation of the hairless mouse ear" Microvasc.Res. 19:374-378
	*	Ferrera and Davis-Smyth, 1997, "The biology of vascular endothelial growth factor" Endocr.Rev. 16:4-25
	*	Friedlander et al., 1995, "Definition of two angiogenic pathways by distinct aV integrins" Science 270: 1500-1502
	*	Hughes et al., 1987, "Adapter plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors" J. Virol. 61: 3004-3012
	*	Kaplan et al., 1994, "Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527" EMBO J 13: 4745-4756
	*	Kiefer et al., 1994, "Endothelial cell transformation by polyomavirus middle T antigen in mice lacking Src-related kinases" Curr.Biol. 4:100-109
	*	Miles & Miles, 1952, "Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs" J. Physiol. 118: 228-257
	*	Nada et al., 1991, "Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src" Nature 351: 69-72
	*	Okada et al., 1991, "CSK: a Protein-tyrosine kinase involved in regulation of src family kinases" J. Biol. Chem. 266(36): 24249-24252
	*	Senger et al., 1983, "Tumor cells secrete a vascular permeability factor that promotes accumulation of ascities fluid" Science 218:983-985
	*	Soriano et al., 1991, "Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice" Cell 64:693-702
RF	*	Stein et al., 1994, "Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice" Genes Dev. 8: 1999-2007

Examiner

*Rebecca Proudy*

Date Considered

*3-4-02*

\*Examiner:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Rev. 5/92)  
Comparable to  
Form PTO-1449

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
TSRI 651.3

Serial No.  
09/538,248

Applicant  
CHERESH, David A., et al.

Filing Date  
March 29, 2000

Group

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RF	✓	van Bruggen, N. et al., 1999, "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain" <u>J. Clin. Invest.</u> 104:1613-1620
	✓	Hanke, J.H. et al., 1996, "Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor" <u>J. Biol. Chem.</u> 271(2): 695-701
	✓	Moasser, M.M. et al., 1999, "Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest" <u>Cancer Res.</u> 59: 6145-6152
	✓	Owens, D.W. et al., 2000, "The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts" <u>Mol. Biol. Cell</u> 11: 51-64
	✓	Maly, D.J., et al., 2000, "Combinatorial target-guided ligand assembly: Identification of potent sub-type selective c-Src inhibitors" <u>PNAS(USA)</u> 97(6): 2419-2424
RF	✓	Rak, J. et al., 1995, "Oncogenes as inducers of tumor angiogenesis" <u>Cancer and Metastasis Reviews</u> 14(4): 263-277

Examiner

Rebecca P. P. P.

Date Considered

3-4-02

\*Examiner:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.